These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33625185)

  • 21. Integrating US-guided FNAB, BRAF
    Ma N; Tian HY; Yu ZY; Zhu X; Zhao DW
    Eur Arch Otorhinolaryngol; 2023 Dec; 280(12):5565-5574. PubMed ID: 37540271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
    Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
    Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer.
    Lee J; Lee CR; Ku CR; Kang SW; Jeong JJ; Shin DY; Nam KH; Jung SG; Lee EJ; Chung WY; Jo YS
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S683-90. PubMed ID: 26215201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S; Sharma C; Afandi B; Al Dahmani K; Al-Zahrani AS; Al Shamsi A; Al Kaabi J
    PLoS One; 2020; 15(4):e0231341. PubMed ID: 32315324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation between conventional ultrasound features and BRAFV600E gene mutation and central lymph node metastasis in thyroid papillary carcinoma].
    Zhang J; Feng Y; He X; Bai Q; Lv Y; Sun K; Qi M
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Mar; 36(3):184-188. PubMed ID: 35193339
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.
    Alzahrani AS; Xing M
    Endocr Relat Cancer; 2013 Feb; 20(1):13-22. PubMed ID: 23132792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
    Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
    Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma.
    Sezer A; Celik M; Yilmaz Bulbul B; Can N; Tastekin E; Ayturk S; Ustun F; Guldiken S; Sut N
    Bosn J Basic Med Sci; 2017 May; 17(2):144-151. PubMed ID: 28284178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.
    Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK
    Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
    Sancisi V; Nicoli D; Ragazzi M; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1745-9. PubMed ID: 22740704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases.
    Shen G; Kou Y; Liu B; Huang R; Kuang A
    Clin Nucl Med; 2018 Jul; 43(7):e215-e219. PubMed ID: 29762246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma.
    Yoon JH; Han K; Lee E; Lee J; Kim EK; Moon HJ; Park VY; Nam KH; Kwak JY
    PLoS One; 2020; 15(2):e0228968. PubMed ID: 32053670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima.
    Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic alterations in papillary thyroid cancers of young patients.
    Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
    Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.